Satya is a DDR focused drug discovery company, and has pioneered RAD51 inhibition as a potentially foundational therapeutic for high replication stress solid tumors. In addition to first- and best-in-class DDR programs, Satya additionally focuses on targeted pan-cancer therapeutics that can address a wide variety of tumors Satya's world-class scientific team is driven by a commitment to excellence, and has experience of working on over 75 targets that have led to over 15 global clinical programs, including one FDA-approved oncology drug